Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial | Eli Lilly and Company

Eli Lilly's retatrutide showed greater A1C reduction (2.2%) and more than double the weight loss (44-47 lbs) compared to Ozempic (1.8%, 21 lbs) in a head-to-head trial with type 2 diabetes patients. Retatrutide also improved cardiovascular risk factors. Common side effects included gastrointestinal issues. Detailed results will be presented at a future medical meeting.

Original reporting
Published Oct 28, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$LLY
Bullish
medium confidence
Mentioned
$LLY
Relevance
8/10
AlphAI data visualization · based on investor.lilly.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The disclosed head-to-head efficacy at 80 weeks versus the highest approved Ozempic dose is a material differentiation datapoint that can shift expectations for Lilly’s pipeline value, trial strategy, and competitive positioning.

02

Market read

Traders get a fresh, comparative efficacy and tolerability snapshot that can re-rate Lilly’s obesity and diabetes pipeline expectations ahead of future conference and peer-reviewed publication.

03

What to watch

GI adverse event rates and higher discontinuation at the higher dose could cap enthusiasm; traders may also focus on whether cardiovascular risk-factor improvements translate into hard outcomes in later trials.

Relevance 8/10Novelty 8/10Timing: today’s Phase 3 head-to-head efficacy disclosure

Background

Lilly is advancing retatrutide, an investigational once-weekly triple hormone receptor agonist, through Phase 3 registrational trials in type 2 diabetes and obesity-related indications.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

Eli Lilly reports TRANSCEND-T2D-2 Phase 3 head-to-head results showing retatrutide A1C down 2.2% vs Ozempic 1.8% at 80 weeks and weight loss 44-47 lbs vs 21 lbs.

Expected impact

Likely upward bias as traders price improved differentiation versus GLP-1 comparators, while monitoring tolerability and the investigational status.

Evidence & confidence

The article discloses specific, comparative Phase 3 efficacy endpoints at 80 weeks plus discontinuation rates, which can move biotech/pharma sentiment even before regulatory filings.

Market effects

Strengthens the competitive narrative for next-gen triple-agonists versus GLP-1s, potentially raising the bar for efficacy and tolerability across the obesity/diabetes sector.

Limited direct regional read-through; primarily impacts US-listed pharma/biotech sentiment and GLP-1 peer positioning.

Could influence global expectations for cardiometabolic drug development timelines and trial designs, given the head-to-head comparator choice.

Counterpoint

Because retatrutide is still investigational and the trial is open-label, the market may discount the magnitude until confirmatory endpoints, safety durability, and regulatory submissions are clearer.

Key entities

  • Eli Lilly and Company

    Sponsor of retatrutide Phase 3 TRANSCEND-T2D-2 head-to-head results versus Ozempic 2 mg.

  • retatrutide

    Investigational once-weekly triple agonist (GIP/GLP-1/glucagon receptor) studied in Phase 3 trials.

  • Ozempic

    Approved injectable GLP-1 comparator at 2 mg in TRANSCEND-T2D-2.

  • TRANSCEND-T2D-2

    Phase 3 randomized trial in adults with type 2 diabetes comparing retatrutide 9 mg and 12 mg versus Ozempic 2 mg at 80 weeks.

Related articles

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$LLYMed

GLP-1 pill vs injection: How do they compare for Canadians? - National

Health Canada approved Eli Lilly's oral GLP-1 pill, Foundayo, for weight loss and Type 2 diabetes. The pill, expected in pharmacies in January, offers a daily alternative to weekly injections like Zepbound. Foundayo's active ingredient, orforglipron, differs from Novo Nordisk's semaglutide-based products, including the pending Wegovy pill. Pricing and insurance coverage vary, with Foundayo listed at US$650 for a 30-day supply in the U.S. without insurance.

$LLYMed

Health Canada Approves Eli Lilly Foundayo Weight Loss Pill

Health Canada approved Eli Lilly's (LLY) oral weight loss pill, Foundayo, for obesity and Type 2 diabetes treatment. The drug, containing orforglipron, is expected to reach pharmacies in January 2027. Experts suggest it may be as effective as existing treatments, but side effects like nausea are common. Foundayo competes with Novo Nordisk's (NVO) Rybelsus, which is approved for diabetes management only.

$LLYMed

Eli Lilly Secures Canada and Australia Approval for Foundayo

Eli Lilly has received approval for its weight-loss drug, Foundayo, in Canada and Australia. The daily oral medication, containing orforglipron, is for adults with obesity, certain overweight-related conditions, and Type 2 diabetes. Health Canada approved it on November 13, with availability expected in January. The TGA approved it in Australia, with availability within days. The drug offers an alternative to injectable GLP-1 treatments.